Advanced HLA DSASAB Class I IgG Antibodies with C1q Screen Test available for $966 USD across USA. Essential for transplant patients in New York
Get comprehensive HLA Pretransplant Workup Non-Sensitized Recipient Panel 1 testing for $556 USD. Essential pre-transplant compatibility assessment for kidney and liver transplant candidates. Available in New York HLA Pretransplant Workup Non-Sensitized Recipient Panel 1 Test Original price was: $618.Current price is: $556.
Sale!

HLA DSASAB Class I IgG Antibodies with C1q Screen Test

Original price was: $1,072.Current price is: $966.

-10%

The HLA DSASAB Class I IgG Antibodies with C1q Screen Test is a sophisticated diagnostic tool designed to detect complement-fixing antibodies that pose significant risks to transplant success. This advanced test specifically identifies IgG antibodies against HLA Class I antigens that can activate the complement system, which is crucial for predicting and preventing organ rejection in transplant recipients. Using cutting-edge Luminex X-Map technology, the test provides highly sensitive detection of antibodies that traditional methods might miss. The test is particularly valuable for patients undergoing kidney, heart, liver, or bone marrow transplantation, as it helps assess immunological compatibility between donor and recipient. Results are typically available within 10-12 days from serum samples, providing critical information for transplant planning and post-transplant monitoring. This comprehensive screening costs $966 USD and offers invaluable insights for optimizing transplant outcomes and patient safety.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

HLA DSASAB Class I IgG Antibodies with C1q Screen Test

Comprehensive Introduction to Transplant Antibody Detection

The HLA DSASAB Class I IgG Antibodies with C1q Screen Test represents a groundbreaking advancement in transplantation medicine, specifically designed to identify antibodies that can trigger complement-mediated organ rejection. This sophisticated diagnostic tool goes beyond conventional antibody screening by detecting IgG antibodies capable of activating the complement cascade through C1q binding. The test’s importance lies in its ability to predict immunological risks that could compromise transplant success, making it an essential component of modern transplant protocols.

What This Advanced Test Measures and Detects

This specialized test employs state-of-the-art Luminex X-Map technology to precisely measure:

  • HLA Class I-specific IgG antibodies with complement-fixing capabilities
  • Antibodies that bind to C1q, initiating the classical complement pathway
  • Immunological risk factors for hyperacute and acute antibody-mediated rejection
  • Donor-specific antibodies that traditional methods may underestimate

Technical Methodology

The test utilizes Luminex X-Map bead-based technology, which allows for simultaneous detection of multiple antibody specificities with exceptional sensitivity and specificity. This advanced platform enables the identification of clinically relevant antibodies that conventional crossmatch techniques might miss, providing transplant teams with comprehensive immunological profiling.

Who Should Consider This Essential Test

This test is critically important for several patient populations undergoing transplantation evaluation:

Pre-Transplant Candidates

  • Patients awaiting kidney, heart, liver, or bone marrow transplantation
  • Individuals with previous transplant history or blood transfusions
  • Patients with known HLA sensitization from pregnancy or prior transplants
  • Candidates for living donor transplantation requiring comprehensive compatibility assessment

Post-Transplant Monitoring

  • Transplant recipients experiencing unexplained graft dysfunction
  • Patients with suspected antibody-mediated rejection
  • Individuals undergoing desensitization protocols
  • Recipients with deteriorating organ function without clear cause

Significant Benefits of Advanced Antibody Detection

Choosing the HLA DSASAB Class I IgG Antibodies with C1q Screen Test provides numerous advantages:

Enhanced Transplant Safety

  • Identifies high-risk antibodies that could cause immediate graft rejection
  • Enables proactive management of immunological barriers to transplantation
  • Reduces the risk of hyperacute and acute antibody-mediated rejection
  • Supports informed donor selection and compatibility assessment

Clinical Decision Support

  • Guides appropriate desensitization strategies when needed
  • Helps determine optimal timing for transplantation
  • Assists in selecting compatible donor-recipient pairs
  • Provides critical information for post-transplant monitoring protocols

Understanding Your Test Results

Interpreting your HLA DSASAB Class I IgG Antibodies with C1q Screen Test results requires professional medical guidance:

Positive Results

  • Indicates presence of complement-fixing HLA Class I antibodies
  • Suggests increased risk for antibody-mediated rejection
  • May require additional immunological workup and intervention
  • Could influence donor selection and transplant timing decisions

Negative Results

  • Suggests absence of detectable complement-fixing antibodies
  • May support proceeding with transplantation planning
  • Should be interpreted in context of complete clinical picture
  • Does not exclude all forms of immunological risk

Clinical Correlation

Your transplant specialist will correlate test results with your complete medical history, current clinical status, and other laboratory findings to develop the most appropriate management strategy for your specific situation.

Test Pricing and Availability

Price Type Amount (USD)
Discount Price $966
Regular Price $1,072

Test Specifications

  • Turnaround Time: 10-12 days
  • Sample Type: 2 mL (1 mL minimum) serum from 1 SST
  • Shipping Requirements: Refrigerated or frozen
  • Required Documentation: Brief clinical history and HLA typing report of donor/donors for pre or post transplantation samples

Nationwide Accessibility and Convenience

We maintain comprehensive testing facilities across the United States, ensuring convenient access to this advanced diagnostic service in major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our nationwide network guarantees consistent quality and reliable results regardless of your location.

Take the Next Step in Your Transplant Journey

Don’t leave your transplant success to chance. The HLA DSASAB Class I IgG Antibodies with C1q Screen Test provides the critical immunological information needed to optimize your transplant outcomes. Our experienced team is ready to assist you with comprehensive testing and expert interpretation.

Call or WhatsApp us today at +1(267) 388-9828 to schedule your test or speak with our transplantation specialists. Take control of your transplant journey with confidence and advanced diagnostic precision.

SKU: 1154 Category:

Related products